Literature DB >> 10841309

Levels, phosphorylation status and cellular localization of translational factor eIF2 in gastrointestinal carcinomas.

M V Lobo1, M E Martín, M I Pérez, F J Alonso, C Redondo, M I Alvarez, M Salinas.   

Abstract

The level of expression and the phosphorylation status of the alpha subunit of initiation factor 2 (eIF2alpha) protein have been determined by comparing samples from human stomach, colon and sigma-rectum carcinomas with normal tissue from the same patients. The unphosphorylated and phosphorylated levels of cytoplasmic eIF2alpha, as well as the percentage of phosphorylated factor over the total, were significantly higher in stomach, colon and sigma-rectum tumours compared with normal tissue. The expression of this factor was also studied by using immunocytochemical methods, where redistribution towards the nucleus in tumour cells as compared with normal tissue was observed. Our results support a likely implication of eIF2alpha in gastrointestinal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841309     DOI: 10.1023/a:1004091122351

Source DB:  PubMed          Journal:  Histochem J        ISSN: 0018-2214


  24 in total

Review 1.  Translational regulator eIF2α in tumor.

Authors:  Qiaoli Zheng; Jingjia Ye; Jiang Cao
Journal:  Tumour Biol       Date:  2014-03-09

2.  Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.

Authors:  Gabrielle Dias Salton; Claudia Cilene Fernandes Correia Laurino; Nicolás Oliveira Mega; Andrés Delgado-Cañedo; Niclas Setterblad; Maryvonnick Carmagnat; Ricardo Machado Xavier; Elizabeth Cirne-Lima; Guido Lenz; João Antonio Pêgas Henriques; Jomar Pereira Laurino
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

Review 3.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 4.  Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations.

Authors:  Azmi Yerlikaya
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

5.  Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors.

Authors:  Sonia Tejada; M Val T Lobo; Mercedes García-Villanueva; Silvia Sacristán; M Isabel Pérez-Morgado; Matilde Salinas; M Elena Martín
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

6.  Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma.

Authors:  N Kunkeaw; S H Jeon; K Lee; B H Johnson; S Tanasanvimon; M Javle; C Pairojkul; Y Chamgramol; W Wongfieng; B Gong; C Leelayuwat; Y S Lee
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

Review 7.  The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

Authors:  Nicholas Burwick; Bertal H Aktas
Journal:  Expert Opin Ther Targets       Date:  2017-10-30       Impact factor: 6.902

Review 8.  Translation initiation and its relevance in colorectal cancer.

Authors:  Emma Minnee; William James Faller
Journal:  FEBS J       Date:  2021-01-24       Impact factor: 5.622

9.  Data mining for gene networks relevant to poor prognosis in lung cancer via backward-chaining rule induction.

Authors:  Mary E Edgerton; Douglas H Fisher; Lianhong Tang; Lewis J Frey; Zhihua Chen
Journal:  Cancer Inform       Date:  2007-02-10

Review 10.  Role of RONS and eIFs in Cancer Progression.

Authors:  Yasmeen Ahmed Salaheldin; Salma Sayed Mohamed Mahmoud; Ebenezeri Erasto Ngowi; Vivian Aku Gbordzor; Tao Li; Dong-Dong Wu; Xin-Ying Ji
Journal:  Oxid Med Cell Longev       Date:  2021-07-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.